Pharmena reports loss reduction in H1 2020

WSE-listed biotechnology company Pharmena published its financial results for the first half of 2020. At that time, consolidated sales revenues amounted to PLN 4.4 million compared to PLN 5.3 million in the first half of 2019. The net loss is PLN 2.7 million (vs. PLN 6.0 million loss in H1 2019). Revenues from sales were to a large extent affected by the situation related to the pandemic and the introduced restrictions in the field of stationary trade, including the pharmaceutical channel.